
Signify Health SGFY
Annual report 2022
added 02-27-2023
Signify Health Cost of Revenue 2011-2025 | SGFY
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Signify Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 440 M | 352 M | 265 M | 247 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 440 M | 247 M | 326 M |
Quarterly Cost of Revenue Signify Health
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 123 M | - | 114 M | - | 100 M | 104 M | 98.5 M | - | 83.4 M | 52.7 M | 67.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 123 M | 52.7 M | 93 M |
Cost of Revenue of other stocks in the Health information services industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cerner Corporation
CERN
|
1 B | - | - | $ 27.9 B | ||
|
Computer Programs and Systems
CPSI
|
176 M | - | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
3.72 B | - | - | $ 2.94 B | ||
|
Accolade
ACCD
|
93.7 M | - | 0.29 % | $ 206 M | ||
|
Evolent Health
EVH
|
1.04 B | $ 4.11 | -0.48 % | $ 385 M | ||
|
Health Catalyst
HCAT
|
166 M | $ 2.34 | -4.82 % | $ 141 M | ||
|
HealthStream
HSTM
|
97.9 M | $ 24.4 | 0.95 % | $ 741 M | ||
|
iCAD
ICAD
|
2.97 M | - | - | $ 102 M | ||
|
Akerna Corp.
KERN
|
15.8 M | - | - | $ 161 M | ||
|
HealthEquity
HQY
|
99.1 M | $ 96.06 | -0.75 % | $ 8.22 B | ||
|
OptimizeRx Corporation
OPRX
|
28.6 M | $ 13.18 | -1.35 % | $ 226 M | ||
|
American Well Corporation
AMWL
|
155 M | $ 4.68 | 1.3 % | $ 70.2 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
883 M | - | -10.39 % | $ 886 M | ||
|
Progyny
PGNY
|
235 M | $ 26.39 | -1.2 % | $ 2.26 B | ||
|
Premier
PINC
|
269 M | $ 28.26 | - | $ 2.33 B | ||
|
GoodRx Holdings
GDRX
|
48.2 M | $ 2.72 | -3.72 % | $ 1.05 B | ||
|
Schrödinger
SDGR
|
75.5 M | $ 18.41 | 1.99 % | $ 1.34 B | ||
|
Omnicell
OMCL
|
641 M | $ 43.31 | -1.25 % | $ 1.99 B | ||
|
1Life Healthcare
ONEM
|
319 M | - | - | $ 3.37 B | ||
|
Phreesia
PHR
|
61 M | $ 16.68 | 2.71 % | $ 910 M | ||
|
So-Young International
SY
|
568 M | $ 2.92 | -5.66 % | $ 232 M | ||
|
R1 RCM
RCM
|
1.16 B | - | - | $ 3.81 B | ||
|
10x Genomics
TXG
|
209 M | $ 15.77 | 2.01 % | $ 1.85 B | ||
|
NantHealth
NH
|
28.8 M | - | -46.64 % | $ 10.4 M | ||
|
NextGen Healthcare
NXGN
|
275 M | - | - | $ 1.6 B | ||
|
Veeva Systems
VEEV
|
677 M | $ 219.17 | -1.81 % | $ 35.2 B | ||
|
Zhongchao
ZCMD
|
6.95 M | $ 0.58 | -3.18 % | $ 3.02 M | ||
|
Teladoc Health
TDOC
|
751 M | $ 7.36 | -2.65 % | $ 1.26 B | ||
|
Tabula Rasa HealthCare
TRHC
|
233 M | - | - | $ 255 M | ||
|
SCWorx Corp.
WORX
|
2.24 M | $ 0.21 | 5.86 % | $ 306 K |